Cost-effectiveness of HIV nonoccupational post-exposure prophylaxis in Australia

HIV Medicine

Volumn 10, Issue 4, 2009, Pages 199-208

  Guinot, D ^a   Ho, M T ^a   Poynten, I M ^b   McAllister, J ^c   Pierce, A ^d   Pell, C ^e   Grulich, Andrew E ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d The Alfred   (Australia)

^e Australasian Soc for HIV Medicine   (Australia)

Author keywords

Australia; Cost effectiveness; HIV; Nonoccupational; Post exposure prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANUS INTERCOURSE; ARTICLE; AUSTRALIA; CONSULTATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG WITHDRAWAL; HEALTH CARE COST; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RETROSPECTIVE STUDY; SEROCONVERSION; UNSAFE SEX; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION; ADULT; AMBULATORY CARE; CLINICAL TRIAL; ECONOMICS; FEMALE; GENERAL PRACTICE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOLOGY; MALE; MULTICENTER STUDY; PATIENT SELECTION; POST EXPOSURE PROPHYLAXIS; PROGRAM EVALUATION; SENSITIVITY AND SPECIFICITY; SEXUAL BEHAVIOR; SUPPLY AND DISTRIBUTION; TRANSMISSION; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; AUSTRALIA; COST-BENEFIT ANALYSIS; FAMILY PRACTICE; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV SEROPREVALENCE; HUMANS; MALE; PATIENT SELECTION; POST-EXPOSURE PROPHYLAXIS; PROGRAM EVALUATION; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 62749186299     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00670.x     Document Type: Article

References (38)

1. Cardo DM, Culver DH, Ciesielski CA et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337: 1485-1490.
2. Roland ME, Neilands TB, Krone MR et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41: 1507-1513.
3. Poynten M, Smith DE, Cooper DA, Kaldor JM, Grulich AE. The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2006; 8: 374-381.
4. Kahn JO, Martin JN, Roland ME et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco NPEP Study. J Infect Dis 2001; 183: 707-714.
5. Schechter M, do Lago RF, Mendelsohn AB et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35: 519-525.
6. Richens J, Edwards SG, Sadiq ST. Can the promotion of post-exposure prophylaxis following sexual exposure to HIV (PEPSE) cause harm? Sex Transm Infect 2005; 81: 190-191; discussion 191-192.
7. Martin JN, Roland ME, Neilands TB et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18: 787-792.
8. Low-Beer S, Weber AE, Bartholomew K et al. A reality check: The cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS 2000; 14: 325-326.
9. Pinkerton SD, Holtgrave DR, Kahn JG. Is post-exposure prophylaxis affordable? Aids 2000; 14: 325.
10. Center for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: Recommendations from the U.S. Department of Health and Human Services. Morb Mortal Wkly Rep 2005; 54: RR-2.
11. Fisher M, Benn P, Evans B et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2006; 17: 81-92.
12. Australian National Council on AIDS, Hepatitis C and Related Diseases (ANCAHRD). Guidelines for the Management and Post Exposure Prophylaxis of Individuals who Sustain Nonoccupational Exposure to HIV. ANCAHRD Bulletin, 28, 2001. Available online: http://www.ashm.org.au/guidelines/ hiv-guidelines/pep/pep-guidelines/
13. Almeda J, Casabona J, Simon B et al. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveill 2004; 9: 35-40. Available online: http://www.ashm.org.au/guidelines/hiv-guidelines/pep/ pep-guidelines/
14. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV. AIDS 1998; 12: 1067-1078.
15. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18: 2065-2073.
16. Braitstein P, Chan K, Beardsell A et al. How much is it worth? Actual vs. expected costs of a population-based post-exposure prophylaxis programme. 1st IAS Conference on Pathogenesis and Treatment. Buenos Aires, Argentina, July 2001 [Abstract 153].
17. Herida M, Larsen C, Lot F, Laporte A, Desenclos JC, Hamers FF. Cost-effectiveness of HIV post-exposure prophylaxis in France. AIDS 2006; 20: 1753-1761.
18. Roland ME. Enhancing the potential benefits of HIV post-exposure prophylaxis. AIDS 2006; 20: 1889-1890.
19. Pinkerton SD, Martin JN, Roland ME, Katz MH, Coates TJ, Kahn JO. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164: 46-54.
20. National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV. Australian Government, Department of Health and Ageing. Sexual Health 2007; 4: 277-283.
21. Francia R, Bourne C. (2005). HIV post exposure prophylaxis (PEP) completion and associated sexually transmitted infection (STI) care at a sexual health clinic. Paper presented at the Australian Sexual Health Conference 2005, Hobart, Australia.
22. NSW HIV Post Exposure Prophylaxis Awareness Campaign Evaluation Report. Available online: http://www.ashm.org.au/pep-research/ 2002.
23. Medicare benefits schedule. Department of Health and Ageing, Canberra, Australia. Available online: http://www9.health.gov.au/mbs/ 2005
24. Pharmaceutical benefits schedule, section 100 items. Department of Health and Ageing, Canberra, Australia. Available online: http://www1.health.gov.au/pbs/scripts/disps100.cfm 2005.
25. Hull P, Rawstorne P, Prestage G et al. Sydney Gay Community Periodic Survey August 2005. Available online: http://nchsr.arts.unsw.edu.au/ pdf%20reports/sydney_gcps_aug2005.doc 16 June 2006.
26. Hull P, Prestage G, Rawstorne P et al. Gay Community Periodic Survey Melbourne 2005. Available online: http://nchsr.arts.unsw.edu.au/ pdf%20reports/melbourne2005.pdf 16 June 2006.
27. UNAIDS. http://www.unaids.org/en/Regions_Countries/Countries/ australia.asp 2004.
28. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2005.
29. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150: 306-311.
30. De Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331: 341-346.
31. De Romero J, Marinovich B, Castilla J et al. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS 2002; 9: 1296-1297.
32. Henderson DK, Fahey BJ, Willy M et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med 1990; 113: 740-746.
33. Return on Investment in Public Health. Appendix G: Lifetime treatment costs of HIV/AIDS: A review. Department of Health and Ageing, Canberra, Australia 2003.
34. Australian Bureau of Statistics. 6401.0 Consumer Price Index, Australia 2006. Available online: http://www.abs.gov.au/ausstats/abs%40.nsf/mf/ 6401.0
35. Henry DA, Hill SR, Harris A. Drug prices and value for money: The Australian pharmaceutical benefits scheme. JAMA 2005; 294: 2630-2632.
36. Mastro TD, de Vicenzi I. Probabilities of sexual HIV-1 transmission. AIDS 1996; 10 (Suppl. A): S75-S82.
37. Lurie P, Miller S, Hecht F, Chesney M, Lo B. Postexposure prophylaxis after nonoccupational HIV exposure: Clinical, ethical, and policy considerations. JAMA 1998; 280: 1769-1773.
38. Baylis F, Ginn D. Expanding access to NPEP: Ethical and legal issues. AIDS Public Policy J 1998; 13: 140-167.